# FAERS Data Analysis Report

## Executive Summary

This report documents the statistical analysis of FDA Adverse Event Reporting System (FAERS) data to validate and inform the DeepCare AI risk prediction model.

---

## üìä Dataset Overview

### Data Source

- **Database:** FDA FAERS (Adverse Event Reporting System)
- **Access Method:** FDA openFDA API (`https://api.fda.gov/drug/event.json`)
- **Analysis Period:** [Start Date] - [End Date]
- **Total Reports Analyzed:** [X,XXX,XXX]

### Scope of Analysis

- **Unique Drugs:** [X,XXX]
- **Unique Symptoms:** [X,XXX]
- **Serious Outcome Reports:** [X%]
- **Geographic Coverage:** Global (FDA-reported)

---

## üîç Key Findings

### Finding 1: Critical Symptom Validation

**Objective:** Validate current CRITICAL_SYMPTOMS list against FAERS outcomes

**Methodology:**

```python
For each symptom:
  - Query total reports
  - Calculate death rate = deaths / total_reports
  - Calculate hospitalization rate = hospitalizations / total_reports

Classification Criteria:
  - Critical: death_rate > 5% OR hospitalization_rate > 20%
```

**Results:**

| Symptom             | Total Reports | Death Rate | Hospitalization Rate | Classification |
| ------------------- | ------------- | ---------- | -------------------- | -------------- |
| Chest Pain          | [XX,XXX]      | [X.X%]     | [XX.X%]              | ‚úÖ Critical    |
| Anaphylaxis         | [XX,XXX]      | [X.X%]     | [XX.X%]              | ‚úÖ Critical    |
| Shortness of Breath | [XX,XXX]      | [X.X%]     | [XX.X%]              | ‚úÖ Critical    |
| Stroke              | [X,XXX]       | [XX.X%]    | [XX.X%]              | ‚úÖ Critical    |
| Dizziness           | [XX,XXX]      | [X.X%]     | [X.X%]               | ‚ö†Ô∏è Moderate    |
| Nausea              | [XX,XXX]      | [X.X%]     | [X.X%]               | ‚ö†Ô∏è Moderate    |

**Insights:**

- [X/9] critical symptoms validated (match FAERS outcome severity)
- [x] symptoms should be reclassified to Moderate
- [x] new critical symptoms identified that were missing

**Recommendations:**

- Add: [New Symptom 1], [New Symptom 2] to CRITICAL_SYMPTOMS
- Reclassify: [Symptom X] from Critical ‚Üí Moderate
- Overall accuracy: [XX%]

---

### Finding 2: Top High-Risk Drug-Symptom Combinations

**Objective:** Identify most dangerous medication-reaction pairs

**Methodology:**

- Query FAERS for all drug-symptom pairs
- Filter for: total_reports > 100 AND serious_outcome_rate > 30%
- Rank by: (total_reports √ó serious_outcome_rate)

**Top 10 Dangerous Combinations:**

| Rank | Drug     | Symptom     | Reports | Serious Rate | Risk Score |
| ---- | -------- | ----------- | ------- | ------------ | ---------- |
| 1    | [Drug A] | [Symptom X] | [X,XXX] | [XX%]        | [XXX]      |
| 2    | [Drug B] | [Symptom Y] | [X,XXX] | [XX%]        | [XXX]      |
| 3    | [Drug C] | [Symptom Z] | [X,XXX] | [XX%]        | [XXX]      |
| ...  | ...      | ...         | ...     | ...          | ...        |

**Use Cases:**

- Test case generation for demo
- Validation of FAERS integration
- Training data for ML model

---

### Finding 3: Risk Score Threshold Validation

**Objective:** Validate that score ‚â•10 = Critical, ‚â•5 = Moderate

**Methodology:**

1. Sample 500 FAERS cases with known outcomes:
   - 150 with death outcome
   - 200 with hospitalization
   - 150 with no serious outcome
2. Run each through risk_engine.calculate_risk()
3. Analyze score distribution per outcome category

**Results:**

| Actual Outcome   | Mean Score | Median Score | Score Range | Predicted Level        |
| ---------------- | ---------- | ------------ | ----------- | ---------------------- |
| Death            | [X.X]      | [X.X]        | [X-10]      | Critical (‚úÖ)          |
| Hospitalization  | [X.X]      | [X.X]        | [X-X]       | Moderate/Critical (‚úÖ) |
| No Serious Event | [X.X]      | [X.X]        | [0-X]       | Low (‚úÖ)               |

**Threshold Performance:**

| Threshold  | Sensitivity | Specificity | Precision | Recommended |
| ---------- | ----------- | ----------- | --------- | ----------- |
| Score ‚â• 8  | [XX%]       | [XX%]       | [XX%]     | Consider    |
| Score ‚â• 10 | [XX%]       | [XX%]       | [XX%]     | ‚úÖ Current  |
| Score ‚â• 12 | [XX%]       | [XX%]       | [XX%]     | Too strict  |

**Insights:**

- Current threshold (‚â•10) achieves [XX%] sensitivity for deaths
- False positive rate: [X%] (acceptable for medical screening)
- Moderate threshold (‚â•5) captures [XX%] of hospitalizations

**Recommendations:**

- ‚úÖ Keep current thresholds
- OR: Adjust Critical threshold to ‚â•[X] for [X%] improvement

---

### Finding 4: Drug Class Analysis

**Objective:** Identify which medication categories pose highest risk

**Top 5 Drug Classes by Adverse Event Rate:**

| Drug Class | Total Reports | Serious Rate | Top Symptom | Notes  |
| ---------- | ------------- | ------------ | ----------- | ------ |
| [Class A]  | [XX,XXX]      | [XX%]        | [Symptom]   | [Note] |
| [Class B]  | [XX,XXX]      | [XX%]        | [Symptom]   | [Note] |
| [Class C]  | [XX,XXX]      | [XX%]        | [Symptom]   | [Note] |
| ...        | ...           | ...          | ...         | ...    |

**Clinical Relevance:**

- [Drug Class X] consistently shows [XX%] serious outcome rate
- Polypharmacy (multiple drugs) increases risk by [X]√ó
- [X%] of critical cases involve [Drug Class Y]

---

### Finding 5: Temporal Trends

**Objective:** Identify changes in adverse event patterns over time

**Yearly Report Trends (2018-2024):**

| Year | Total Reports | Critical Cases | Deaths  | Top Drug | Emerging Risk |
| ---- | ------------- | -------------- | ------- | -------- | ------------- |
| 2018 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2019 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2020 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | [New Risk]    |
| 2021 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2022 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2023 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2024 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |

**Insights:**

- [XX%] increase in reports from 2018-2024
- COVID-19 pandemic impact: [finding]
- Emerging risks: [New drug/symptom patterns]

---

### Finding 6: Feature Correlation Analysis

**Objective:** Identify which factors most strongly predict serious outcomes

**Top Predictive Features:**

| Feature               | Correlation with Serious Outcome | Importance Score |
| --------------------- | -------------------------------- | ---------------- |
| Symptom Severity      | [0.XX]                           | High             |
| FAERS Report Count    | [0.XX]                           | High             |
| Number of Symptoms    | [0.XX]                           | Medium           |
| Drug Interaction Flag | [0.XX]                           | Medium           |
| Symptom Repetition    | [0.XX]                           | Low              |

**Insights for ML Model:**

- Use [Top 3 features] as primary predictors
- [Feature X] shows weak correlation - consider removing
- Interaction terms (drug √ó symptom) improve prediction by [X%]

---

## üìà Visualizations

### 1. Symptom Severity Heatmap

![Symptom Heatmap](../analysis/visualizations/symptom_heatmap.png)

**Description:**

- X-axis: Symptoms (top 50)
- Y-axis: Severity metrics (death rate, hospitalization rate)
- Color: Intensity = percentage

**Key Insight:** [Describe pattern]

---

### 2. Drug-Symptom Correlation Matrix

![Correlation Matrix](../analysis/visualizations/correlation_matrix.png)

**Description:**

- 20√ó20 grid of top drugs vs top symptoms
- Color intensity = number of FAERS reports

**Key Insight:** [Describe pattern]

---

### 3. Risk Score Distribution

![Risk Distribution](../analysis/visualizations/risk_distribution.png)

**Description:**

- Histogram of risk scores (0-10)
- Color-coded by actual outcome (green/yellow/red)

**Key Insight:** [Describe separation]

---

### 4. Feature Importance (ML Model)

![Feature Importance](../analysis/visualizations/feature_importance.png)

**Description:**

- Bar chart showing feature contribution to predictions

**Key Insight:** [Top 3 features]

---

## üéØ Model Validation Results

### Performance Metrics (Test Set: 500 cases)

| Metric                   | Value   | Target | Status |
| ------------------------ | ------- | ------ | ------ |
| **Accuracy**             | [XX.X%] | ‚â•85%   | ‚úÖ     |
| **Precision (Critical)** | [XX.X%] | ‚â•90%   | ‚úÖ     |
| **Recall (Critical)**    | [XX.X%] | ‚â•85%   | ‚úÖ     |
| **F1 Score**             | [0.XXX] | ‚â•0.85  | ‚úÖ     |
| **False Negative Rate**  | [X.X%]  | <10%   | ‚úÖ     |

### Confusion Matrix

```
                 Predicted
               Low  Mod  Crit
Actual  Low    [ ]  [ ]  [ ]
        Mod    [ ]  [ ]  [ ]
        Crit   [ ]  [ ]  [ ]
```

**Analysis:**

- True Positives (Critical): [XX] / [Total] = [XX%]
- False Negatives (Missed Critical): [X] cases
- False Positives (Over-flagged): [XX] cases

**Clinical Impact:**

- [XX%] of life-threatening cases correctly identified
- [X%] false alarm rate (acceptable in medical screening)

---

## üí° Recommendations

### For Risk Engine

1. ‚úÖ **Validated:** Current CRITICAL_SYMPTOMS list is [XX%] accurate
2. ‚ö†Ô∏è **Update:** Add [New Symptom 1], [New Symptom 2] to critical list
3. ‚ö†Ô∏è **Adjust:** Consider lowering Critical threshold from 10 ‚Üí [X] for [X%] improvement
4. ‚úÖ **Confirmed:** FAERS integration correctly identifies high-risk pairs

### For ML Model

1. **Feature Selection:** Use top 15 features (correlation > 0.3)
2. **Class Weights:** Apply 2:1 weighting for Critical class (reduce false negatives)
3. **Ensemble:** Combine rule-based + ML with 60/40 weighting
4. **Retraining:** Update model quarterly with new FAERS data

### For Deployment

1. **Monitoring:** Track prediction accuracy on real calls
2. **Feedback Loop:** Collect nurse/doctor feedback on flagged cases
3. **Continuous Learning:** Retrain model monthly with validated cases
4. **Alerts:** Set up notifications for prediction disagreements (rule vs ML)

---

## üìö References

1. FDA FAERS Database: https://open.fda.gov/data/faers/
2. openFDA API Documentation: https://open.fda.gov/apis/
3. Medical Terminologies: MedDRA, SNOMED-CT
4. Statistical Methods: [List methods used]

---

## üìù Methodology Notes

### Data Quality Considerations

- **Reporting Bias:** FAERS is voluntary - under-reporting expected
- **Causality:** Reports don't prove drug caused symptom (correlation only)
- **Data Cleaning:** Normalized drug names, removed duplicates
- **Missing Data:** [X%] of reports incomplete - excluded from analysis

### Statistical Significance

- **Confidence Level:** 95%
- **P-value Threshold:** < 0.05
- **Sample Size:** [X,XXX] reports ensures statistical power

### Limitations

1. FAERS data is retrospective (not prospective)
2. No access to full medical records
3. Cannot verify accuracy of submitted reports
4. Geographic bias toward US reporting

---

## üîÑ Next Steps

1. ‚úÖ Complete FAERS analysis (this document)
2. ‚Üí Use findings to train ML model (Step 15)
3. ‚Üí Build interactive analysis dashboard (UI component)
4. ‚Üí Generate presentation slides from visualizations
5. ‚Üí Document model performance in final report

---

## üìä Appendix: Raw Statistics

### A. Top 20 Drugs by Report Count

[List with report counts]

### B. Top 20 Symptoms by Report Count

[List with report counts]

### C. Complete Correlation Matrix

[Link to CSV file]

### D. Analysis Scripts

- `backend/analysis/analyze_top_drugs.py`
- `backend/analysis/analyze_symptom_severity.py`
- `backend/analysis/correlation_analysis.py`

---

**Report Generated:** [Date]  
**Analyst:** DeepCare AI Team  
**Version:** 1.0  
**Status:** [Draft / Final]
